Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for November 2010
November 1, 2010
- NanoViricides, Inc. Reports Dramatically Extended Survival for FluCide Treated Animals in an Influenza Lethality Study
- Algeta ASA (NO) - Algeta to present on the preparation and use of Alpharadin in a clinical setting at the 52nd ASTRO annual meeting
- Merck's Investigational Medicine Boceprevir Achieved Significantly Higher SVR Rates In Treatment-Failure and Treatment-Naïve Adult Patients with Chronic Hepatitis C Genotype 1 Compared to Control
- Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at the EORTC-NCI-AACR Meeting
- Medivir Notes that Partner Tibotec Announced Week 24 Interim Results from Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD
- New Data on Odanacatib, Merck?s Investigational Cat-K Inhibitor for Osteoporosis, Presented at the Annual Meeting of The American Society for Bone and Mineral Research
- Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon
- GI-5005 HCV Therapeutic Vaccine Increases SVR Prior Treatment Failures
- Idera Pharmaceuticals Presents Phase 1 Data on IMO-2125 Demonstrating Induction of Broad Antiviral Immune Response in Null-Responder HCV Patients
- New Data Analyses on Concerta Pediatric Treatment Include Insight on Handwriting Performance and Attention in ADHD
- New Data From Phase 3 Studies Showed Superior SVR (Viral Cure) Rates Achieved with Telaprevir-Based Combination Therapy in People with Hepatitis C, Regardless of Race or Stage of Liver Disease
- NeurAxon Announces NXN-188 Phase 2 Data Demonstrating Efficacy in Acute Migraine
- Viread for Hepatitis B Maintains Antiviral Suppression with No Development of Resistance Through Four Years of Treatment
- Final Results of Clinical Trial on Boceprevir
- Gilead's Investigational Hepatitis C Compounds GS 9190 and GS 9256 in Combination with Standard of Care Therapies Achieve Substantial Viral Suppression in Phase II Study
- ANA598 Data Presented at AASLD Highlight Positive Clinical Profile of DAA Entering Phase IIb
- Mayo Researchers Find Mortality Rates from Liver Diseases Underestimated
- BioCancell Announces Success in Phase I/IIa Pancreatic Cancer Clinical Trial
- OctoPlus' licensee Biolex presents significant tolerability advantages of Locteron at AASLD conference today
November 2, 2010
- Inhibitex Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
- Hyperion Therapeutics' Glycerol Phenylbutyrate Meets Primary Endpoint in Phase III Pivotal Study in Urea Cycle Disorders
- Romark Announces Data Presented at AASLD Meeting 2010
- RegeneRx Reports Positive Results of Preclinical Dry Eye Study
- Ironwood Pharmaceuticals Announces Conference Call to Discuss Positive Linaclotide Phase 3 IBS-C Results
- Ironwood and Forest Announce Positive Linaclotide Results from Second Phase 3 Trial in Patients with Irritable Bowel Syndrome with Constipation
- CeNeRx's Novel Antidepressant TriRima Demonstrates Key Safety Benefit in Pivotal Safety Study
- Telbivudine Given to Mothers With Hepatitis B Reduces Infection Rate in Infants
- Almirall and Ironwood Announce Positive Results from the Second Phase 3 Trial of Linaclotide in Patients with Irritable Bowel Syndrome with Constipation
- Avila Presents New Data on its Novel, Orally-Available Targeted Covalent Drug, AVL-192
- Nile Therapeutics Phase 2 Study of CD-NP in Patients With Acute Decompensated Heart Failure Meets Primary Endpoint, Has Favorable Trends on Renal Function
- Aeolus Pharmaceuticals' AEOL 10150 Promotes Survival in Non-Human Primates Exposed to Lethal Doses of Radiation
- Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
- NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX-1998 Liquid Capsaicin Formulation
- Symbicort (budesonide/formoterol fumarate dihydrate) Study in African American Patients With Asthma Shows Improved Lung Function Compared to Budesonide Alone
- Increased SVR and Decreased Adverse Events Reported in Final Results of Phase 3 Study on Telaprevir
November 3, 2010
- IMC - Immuron Presents Clinical Data at Liver Conference
- EUSA Pharma Announces 10-Year Outcome Data Demonstrating Utility of Prostascint in Guiding Prostate Cancer Radiotherapy and Improving Disease-Free
- Medication Use Evaluation of ENTEREG (alvimopan) Published in the November Edition of The Annals of Pharmacotherapy
- Soligenix Announces Completion of Enrollment and Preliminary Safety Results of a Phase 1B Clinical Trial for RiVax
- GenVec Announces Presentations at the 2010 American Society of Tropical Medicine and Hygiene Meeting
- EUSA Pharma Announces 10-Year Outcome Data Demonstrating Utility of PROSTASCINT in Guiding Prostate Cancer Radiotherapy and Improving Disease-Free Survival
- Onbrez Breezhaler From Novartis Provides Greater Clinical Benefits Than Tiotropium in New Study of COPD Patients
- Alpharadin found to be safe and easy to use in patients with bone metastases resulting from CRPC
- Cempra Pharmaceuticals' Solithromycin (CEM-101) Demonstrates Potent In Vitro and In Vivo Activity Against Malaria
- Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial
- Cellonis' Cell Treatment for Glioma May Prevent Tumor Recurrence and Improve Quality of Life Significantly
November 4, 2010
- Shire Presents Positive New Data at the 60th Annual American Society of Human Genetics (ASHG) for Patients with Type 1 Gaucher Disease
- PolyMedix Announces Acceptance of Two Presentations at the American Heart Association Meeting
- Study in NEJM Shows Novartis Drug Afinitor Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
- Napo Pharmaceuticals, Inc. Announces That Crofelemer Demonstrates Highly Statistically Significant Results in the Treatment of Chronic Diarrhea in People Living With HIV/AIDS
- 4SC's Vidofludimus Meets Primary Endpoint with Excellent Response Rate in IBD Trial
- Merck KGaA: Top-Line Results of Long-Term Study of Safinamide as Add-on Treatment to Levodopa in Advanced Parkinson?s Disease
- Tikcro Announces Results of BioCancell's US FDA Phase I/IIa Pancreatic Cancer Trial
- Data from Brentuximab Vedotin (SGN-35) Phase I Clinical Trial Published in New England Journal of Medicine
November 5, 2010
- Provectus Reports Full Phase 2 Study Data on PV-10 for Metastatic Melanoma
- New data show potential for Novartis Meningitis B vaccine (4CMenB) candidate to cover majority of diverse meningococcal serogroup B strains
- Xeomin (incobotulinumtoxinA) Data To Be Presented At The 71st Annual Assembly Of The American Academy Of Physical Medicine And Rehabilitation
- Heightened Interest from the Medical Research Community and New Funding of International Stem Cell Corporation's (ISCO) Therapeutic Research
- AiCuris Presents Preclinical and Phase 1 Data of its anti-HSV drug AIC316
- Genentech Reports Promising Phase II Results with New Targeted Approach in Advanced Melanoma
- New Ph II Data for PLX4032 (RG7204) Shows 52% Response Rate in Metastatic Melanoma
- EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist
- Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
- Plexxikon Announces Preliminary PLX4032 Phase 2 Data Confirming Substantial Response Rate in Metastatic Melanoma Patients
- Mayo Clinic Finds Insufficient Vitamin D Levels in CLL Patients Linked to Cancer Progression and Death
- Cycloset Data to Be Presented in Poster Session at 8th Annual World Congress on Insulin Resistance, Diabetes & CVD
November 8, 2010
- Actemra Data Presented at ACR Annual Meeting On Rapid Response and Long-Term Efficacy in People With Rheumatoid Arthritis
- MAP Pharmaceuticals Announces Successful Results for LEVADEX Thorough QT Trial
- Ardea Biosciences Announces Positive Results for RDEA594 in Combination with Febuxostat or Allopurinol in Gout Patients
- Analysis Shows Topical NSAID Has Potentially Better Gastrointestinal Safety Profile Than Oral NSAIDs in Treatment of Knee Osteoarthritis
- New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving Remicade After Inadequate Response to Enbrel Or Humira Demonstrate Marked Clinical Improvement
- In First Phase 3 Trial, Tasocitinib (CP-690,550), an Oral JAK Inhibitor, Administered as Monotherapy, Reduces Signs and Symptoms of Active Rheumatoid Arthritis and Improves Physical Function
- New Magnetic Resonance Imaging (MRI) Data Show Efficacy of Simponi in Treatment of Rheumatoid Arthritis
- New Data Show That Subcutaneous Injection of An Investigational Formulation of Orencia (Abatacept) Provided Similar Improvements in Disease Activity Compared to Intravenous Administration of Orencia
- Abbott Presents Data Exploring Relationship of Physical Function to Inflammation and Structural Damage in RA
- Seattle Genetics and Millennium to Present Brentuximab Vedotin (SGN-35) Clinical Data at American Society of Hematology Annual Meeting
- Louisiana State University Health Sciences Center Research Shows Fish Oil Component Given Up to 5 Hours After Stroke Limits Brain Damage
- ExonHit Presents Promising Data on Genomic Biomarkers in Alzheimer's Disease Clinical Trials
- YM Biosciences Reports Significant Response Rates in Anemia, Splenomegaly, and Constitutional Symptoms From the Phase I/Ii Trial of Its Jak1/Jak2 Inhibitor, Cyt387, in Myelofibrosis
- Synageva BioPharma Presents Data at the American Society of Human Genetics on SBC-102 for Lysosomal Acid Lipase Deficiency
November 9, 2010
- Micromet to Provide Update on BiTE Antibody R&D Programs at 2010 American Society of Hematology Annual Meeting
- Emergent BioSolutions Announces Acceptance of TRU-016 and TRU-Adhance Abstracts for Presentation at American Society of Hematology Meeting
- EntreMed ENMD-2076 Phase 1 Data in Hematological Studies to be Presented at ASH
- TONIX Pharmaceuticals Reports Analysis of Phase 2a Study of Very Low Dosage Cyclobenzaprine in Fibromyalgia Syndrome (FMS)
- Lorcaserin Phase 3 Clinical Trial in Patients with Type 2 Diabetes Shows Statistically Significant Weight Loss
- Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus
- Absorption Systems to Present at the Combined 2010 American Association of Pharmaceutical Scientists and Pharmaceutical Sciences World Congress Meeting
- Data Presented at ACR Meeting Demonstrate Safety of Colcrys (Colchicine, USP) for Treatment of Gout Flares in Patients with Multiple Co-Morbid Conditions
- Idera Pharmaceuticals Presents Preclinical Data from its Autoimmune Disease Program at the 74th Annual Scientific Meeting of the American College of Rheumatology
- New Cimzia (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
- Drug Regarded as Alternative to Standard Treatment for Preventing Relapse of Certain Type of Vasculitis Does Not Appear as Effective
- ChemoCentryx Reports Favorable Phase I Results for CCX354 in Patients With Rheumatoid Arthritis at the Annual American College of Rheumatology Meeting (ACR)
- New Study Data Demonstrate Restylane Positively Impacts People's First Impressions
- Nuvo Research Announces Positive Top-Line Wf10 Phase 2 Trial Results
- Denosumab superior to Zometa in delaying/preventing bone complications in advanced breast cancer patients -- data published today in Journal of Clinical Oncology
- Chimerix Antiviral CMX001 Inhibits JC Virus Replication in Preclinical Study; Late-Breaker Presented at Antiviral Congress 2010
- Santarus Announces Positive Top-Line Results in E.U. Phase III Clinical Study Evaluating Budesonide MMX in Ulcerative Colitis
- Rexahn Pharmaceuticals Announces Publication of New Preclinical Research Data for Novel Anticancer Compounds
- BioCryst to Present New Data for BCX4208 Monotherapy at the 74th Annual American College of Rheumatology (ACR) Scientific Meeting
November 10, 2010
- Aeterna Zentaris to Present Phase 2 Results for AEZS-108 in Endometrial Cancer at Major Conference in Germany
- Researchers Discover Important Link Between Adrenal Gland Hormone and Brain in Hypertension
- How Well Does Clot-busting Drug Work in Stroke Patients?
- ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
- New NIH Data Show Gains in COPD Awareness
- Trojan Horse Ploy to Sneak Protective Drug into Brains of Stroke Patients
- Positive XOMA 052 Results in Inflammatory Eye Disease - Behcet's Uveitis - Presented at American College of Rheumatology Scientific Meeting
- Silence's Atu027 Prevents Cancer Spread to Lungs - Peer Review Paper Published
- Watson Announces Top Line Uracyst U.S. Pilot Study Results
- Alnylam Presents Additional Interim Phase I Data for ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancer
November 11, 2010
- Geron Announces Two Publications Demonstrating That Its Telomerase Inhibitor Drug Targets Cancer Stem Cells
- Incyte's Selective Oral JAK1 and JAK2 Inhibitor Demonstrates Positive Phase IIa Results in Patients with Active Rheumatoid Arthritis
- Access Pharmaceuticals Presents CobOral Insulin Research at 10th Annual Diabetes Technology Meeting on November 11-13, 2010
- Novartis Discontinues ASA404 Clinical Trial Program and Shifts Focus to Other Cancer Compounds in Early and Late Stage Development
- NexBio Presents Data at ACAAI 2010 Demonstrating Mechanism of Action for Improvement in Airway Function by DAS181 (Fludase)
- New Analyses of Data From RE-LY Trial, Involving Oral Anticoagulant Pradaxa, to be Presented at American Heart Association's Scientific Sessions
- Reata Pharmaceuticals to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease
November 12, 2010
- Stem Cell Study Shows Benefits in Treatment of Spinal Injuries
- Furiex Reports Positive Phase II Results for Broad Spectrum Quinolone Antibiotic in Complicated Skin Infections
- Antisoma announces outcome of ASA404 ATTRACT-2 trial
- Study Published in New England Journal of Medicine Shows Nplate Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP
- Noninvasive brain stimulation helps improve motor function in stroke patients
- Pharmaxis Previews New Bronchial Challenge Test at the Annual Meeting of the American College of Allergy, Asthma and Immunology
- Watson Announces Top Line Uracyst U.S. Pilot Study Results
- Pevion's Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
November 15, 2010
- Teva Highlights QNAZE HFA Phase III Data at the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology
- Adding Inspra (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity in Patients With Chronic Heart Failure With Mild Symptoms, Study Shows
- Rivaroxaban Significantly Reduces Risk of Stroke in Patients With Atrial Fibrillation With Comparable Safety vs. Warfarin in Pivotal Phase 3 Study
- Curis to Present CUDC-101 Phase I Clinical Data and CU-201 Preclinical Data at the 22nd EORTC-NCI-AACR Symposium
- New Phase III Data Analysis for BiovaxID, Personalized Lymphoma Vaccine, to Be Presented at ASH Annual Meeting
- Mercury Linked to Alzheimer's Disease
- Amakem Receives 1.28M? Government Funding for COPD Drug Development Program
- PolyMedix Presents PMX-60056 Clinical Data at the American Heart Association Scientific Sessions Meeting
- Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD
- Cardium Reports on Presentation at American Heart Association Meeting Relating to Gene Delivery to the Heart and Generx Clinical Development
- New study findings show no benefit of prescription omega-3 fatty acids in prevention of recurrent symptomatic atrial fibrillation in affected patients
- Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
- Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data
- Celladon Corporation Announces MYDICAR Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo
- Targeted Genetics' Partner Celladon Corporation Reports 12 Month Follow Up Data from Phase 2 Clinical Trial of Patients Treated With MYDICAR
- Epizyme Publication Identifies Novel Opportunity for Treatment of Genetically-Defined Human B-cell Lymphomas
- Diffusion Pharmaceuticals Achieves Positive Results in Phase I/II Clinical Trial of Trans Sodium Crocetinate in Peripheral Artery Disease
November 16, 2010
- AlphaRx To Present GAI-122 and Zysolin Pre-Clinical Study Data At AAPS Annual Meeting
- New Treatment for Lung Cancer Shows Promise Non-Invasive, Inhalable Powder Increases Survival Rates
- Erythropoietin Counteracts Breast Cancer Treatment with Herceptin
- 4SC to Highlight the Potential of Its Oncology Compounds at the 22nd EORTC-NCI-AACR Symposium 'on Molecular Targets and Cancer Therapeutics'
- Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
- Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
- Positive Results in Phase I/II Clinical Trial of TSC in PAD
- Mortality Data Presented for Patients Treated with Efient/Effient (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery
- Use of Omega-3 Does Not Appear to Reduce Recurrence of Atrial Fibrillation
- Mirna Therapeutics Presents New Data on microRNA Replacement Therapy Approach at CPRIT's Innovations in Cancer Prevention & Research Conference
- Positive outcome for VR040 in Parkinson?s trial 16 November 2010
- Mesoblast Limited (ASX:MSB) Announce Positive Results Of Novel Heart Attack Treatment Presented At Premier USA Cardiology Conference
- MedImmune Focused on Revolutionizing Cancer Care
November 17, 2010
- Additional Phase 3 Clinical Trial Data Published in Annals of Neurology Showing Dalfampridine Extended Release Tablets Improved Walking Ability in People with Multiple Sclerosis
- NanoViricides Announces Dramatic Viral Load Reduction in Lethal In Vivo Influenza Study
- Cardio3 BioSciences Announces Positive Outcome of the C-Cure Phase II Clinical Trial in Heart Failure Patients
- Peregrine's Bavituximab Demonstrates Broad Potential in Viral Hemorrhagic Fever Infection Models
- Enzon Presents Data at 2010 EORTC-NCI-AACR Meeting
- New Findings Show Bioequivalence, Ease-of-Use and Efficiency of MannKind's Drug Delivery Platform
- Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session
- Study Highlights Incidence of Cardiovascular Disease-Related Events and All-Cause Hospitalizations Associated With Byetta Compared to Insulin, Thiazolidinediones, Sulfonylureas, Metformin and Januvia
- Millennium Research Group Has Released Its Latest Imaging Research Data
- Inovio Pharmaceuticals' HIV DNA Vaccine Achieves Strong T-Cell Immune Responses in Phase I Human Trial
November 18, 2010
- Exelixis Reports Promising Interim Data From Patients With Ovarian Cancer Treated With XL184
- Impax Pharmaceuticals Announces IPX066 Demonstrates Efficacy and Safety in APEX-PD Phase III Study in Treatment of Early Parkinson's Disease
- Intercell announces initial results of Phase II clinical trial evaluating V710 an investigational Staphylococcus aureus vaccine, in patients with end-stage renal disease
- Zalicus to Present Data on Oncology Programs at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Meeting
- Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors
- Exelixis Reports Promising Interim Data from Patients with Castration-Resistant Prostate Cancer Treated with XL184
- Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany
- NicOx presents NCX 6560 phase 1b results at AHA
- In Phase III Study Merck's Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
- New England Journal of Medicine Publishes Phase 2 Study of VX-770 as a New Approach to Treat the Underlying Cause of Cystic Fibrosis
November 19, 2010
- AVEO's Anti-RON Monoclonal Antibody Program Highlighted in Late-Breaker Plenary Presentation at EORTC-NCI-AACR Symposium
- ZIOPHARM Presents New Darinaparsin Preclinical Data at EORTC-NCI-AACR Meeting
- ImmunoGen, Inc. Presents Encouraging Clinical Data for IMGN388
- Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
- Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)
- Galderma Announces Results of Largest-Ever Rosacea Trial
- Analysis of Longer-Term Clinical Study Suggests Psychiatric Hospitalization Rates Decreased in Adults with Schizophrenia Treated with INVEGA(R) SUSTENNA(R)
- FibroGen Announces Phase 2a Results for Investigational Oral Anemia Therapy FG-4592 Will Be Presented at American Society of Nephrology (ASN) Renal Week
- Acceleron's ACE-041 Demonstrates Clinical Efficacy in Advanced Cancer Patients
- Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
- Circassia Achieves Major Reduction in Allergic Reactions to House Dust Mite in Phase II Clinical Study of Novel T-cell Vaccine
- Medivir Announces Positive 24-week Interim Data of TMC435 From the ASPIRE Study (C206)
- Professor Zvi Ram Presents Phase III Recurrent Glioblastoma Survival and Quality of Life Data from the First Pivotal Study of the NovoTTF-100A at the 15th Annual Society for Neuro-Oncology (SNO) Scientific Meeting
November 21, 2010
November 22, 2010
- Interim Results From Independent Study of H.P. Acthar Gel in Patients With Advanced Diabetic Nephropathy Presented at American Society of Nephrology 43rd Annual Meeting
- Stealth Peptides' Bendavia Presented at 2010 American Heart Association's Scientific Sessions
- PolyMedix Announces Three Presentations at Upcoming American Society of Hematology Meeting
- Clinical Data, Inc. Announces Vilazodone Data Featured at the 2010 U.S. Psychiatric & Mental Health Congress
- New Data on H.P. Acthar Gel in the Treatment of Nephrotic Syndrome Presented at the American Society of Nephrology 43rd Annual Meeting
- Paclitaxel Poliglumex (OPAXIO) Combined with Temozolomide and Radiotherapy Demonstrates High Response Rates with Encouraging Progression Free Survival in Malignant Brain Cancer
- Vytorin (ezetimibe/simvastatin) Significantly Reduced Major Vascular Events in Patients With Chronic Kidney Disease in a New 9,000-Patient Investigational Study
- Bayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies with VEGF Trap-Eye in Wet Age-related Macular Degeneration
- Neurocrine Biosciences Announces Successful Completion of Daisy PETAL Study
- Chimerix's Broad-Spectrum Antiviral CMX001 Shown in Animal Model to be a Potent Inhibitor of Herpes Simplex Viruses
- Winston Pharmaceuticals, Inc. Announces Positive Results of Phase II Clinical Trial of Dolorac Nasal Solution
- New Low-Cost Method to Deliver Vaccine Shows Promise
- Celldex Therapeutics Reports Positive Results from Rindopepimut Phase 2 Brain Cancer Study at SNO 2010
- Regeneron Schedules November 22, 2010 Teleconference and Webcast to Discuss Results of Two Phase 3 Studies with VEGF Trap-Eye in Wet Age-related Macular Degeneration
- Good News for Kidney Patients: World's Largest Kidney Disease Trial Shows Big Benefits From Reducing Cholesterol
- Reata and Abbott Announce Positive Phase 2b Study Results for Bardoxolone Methyl
- FibroGen Announces Phase 2a Results for Investigational Oral Anemia Therapy FG-4592 Will Be Presented at American Society of Nephrology (ASN) Renal Week
- Gene Links to Anorexia Found by Children's Hospital of Philadelphia Researchers
November 23, 2010
- Statement of Dr. Larry Corey on the Results of the iPrEx Study of HIV Prevention
- Evidence That Daily Antiretroviral Pill Reduces HIV Risk in Gay Men is a Major Breakthrough Says AVAC
- Global Campaign for Microbicides Lauds Milestone in HIV Prevention Findings that Daily use of Anti-Retroviral Protects Against HIV Infection
- Epizyme Announces Oral Presentations at 52nd ASH Annual Meeting and Exposition in Orlando, Florida
- Abbott Announces Positive Results from Phase 2 Study of Low Dose Atrasentan for Treatment of Diabetic Kidney Disease
- BioAlliance Pharma Presents Preclinical and Phase I Clinical Results with Its AMEP Biotherapy for Metastatic Melanoma
- A Divide and Conquer Strategy for Childhood Brain Cancer
- Under suspicion: The painkiller ziconotide could increase suicidal ideation
- Study shows antiretroviral drugs can prevent HIV in men who have sex with men
- U.S. death rate from congenital heart defects continues to decline
- Study examines risk of bleeding among patients taking 2 anti-platelet drugs
- Early diagnosis of rheumatoid arthritis crucial to positive outcomes for patients
- Daily Dose of HIV Drug Reduces Risk of HIV Infection
- Use of HIV medications reduces risk of HIV infection in uninfected people
November 24, 2010
November 29, 2010
- Oncolytics Biotech Inc. Announces Publication of Phase I Clinical Trial Results Examining Combination of REOLYSIN and Docetaxel in Clinical Cancer Research
- Updated Clinical Data on ARIAD's Investigational pan-BCR-ABL Inhibitor, Ponatinib, to Be Presented at Annual American Society of Hematology Meeting
- Celator Pharmaceuticals Announces Data to be Presented at the American Society of Hematology Annual Meeting
- Verona Pharma plc Proof of Concept Studies confirm RPL554 delivery possible via industry-standard inhaler devices
- Renovo Positive Data for Juvista
- Zalicus to Present Data on Novel A2A Agonist Oncology Program at the American Society for Hematology Meeting
- Avila Scientists Publish Research Demonstrating First-Ever Covalent Irreversible Inhibition of a Protease Central to Hepatitis C Infection
- Merck Reports Initial Results of Phase III Study of ISENTRESS (raltegravir) Investigational Once-Daily Dosing in Treatment-Naïve Adult Patients Infected with HIV-1
- Amarin's AMR101 Meets Pivotal Phase 3 Study Endpoints With Highly Statistically Significant Reductions in Triglycerides at 4 Gram and 2 Gram Doses in MARINE Trial With No Statistically Significant Increase in LDL-C and Safety Profile Similar to Placebo
- Calistoga Pharmaceuticals Announces Oral and Poster Presentations at American Society of Hematology (ASH) Annual Meeting
- Positive results for Ark's pre-clinical product candidate EG013 in the treatment of foetal growth restriction
- GeoVax Labs, Inc. Strategy Supported by Encouraging Results of European Therapeutic HIV/AIDS Vaccine Trial
- Pfizer to Present Data from Its Hematology Portfolio at the 52nd Annual Meeting of the American Society of Hematology
- New Discovery May Offer Cure for Human Papillomavirus (HPV)
- Amarin to Host Conference Call at 8:30 a.m. EST on November 29, 2010, to Discuss Top-Line Results of Phase 3 MARINE Study of AMR101 in Patients with Very High Triglycerides
- Pharming announces topline study results on prophylactic use of Ruconest in Hereditary Angioedema
- Successful ASSERT Trial Results in Resverlogix Filing New RVX-208 Patent
- Discovery Halts Breast Cancer Stem Cells
- Abnormal Blood Vessel Function Found in Women with Broken Heart Syndrome
November 30, 2010
- Cyrenaic Pharmaceuticals Reports Improvement of Negative Symptoms and Cognition in Schizophrenia Patients Treated with CYR-101
- Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1 NP001 Study in the Treatment of Amyotrophic Lateral Sclerosis (ALS)
- Photocure announces positive preliminary results from the Allumera consumer trial
- Studies Reconfirm Significant Benefits Regarding the Use of SIR-Spheres Microspheres for the Treatment of Inoperable Liver Tumors
- New Data on Vimpat (lacosamide) C-V to be Presented at the 64th Annual Meeting of the American Epilepsy Society
- 10th Colloque Médecine et Recherche of the Fondation Ipsen in the Endocrinology Series: ?Multi-System Endocrine Disruption?
- Cytheris Announces Publication of Clinical Case Study Combining Recombinant Human Interleukin-7 (CYT107) with Antiviral Agent CMX001 as Potential Treatment for Progressive Multifocal Leukoencephalopathy (PML)
- Lubiprostone Successfully Completes Long-Term Phase 3 Safety Trial in Japanese Patients with Chronic Idiopathic Constipation
- Keryx Biopharmaceuticals Announces Highly Statistically Significant Positive Results From Phase 3 Study of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in Dialysis Patients
- Cytheris announces publication of clinical case study combining recombinant human interleukin-7 (CYT107) with antiviral agent CMX001 as potential treatment for progressive multifocal leukoencephalopathy (PML)
- New MRI Data Confirm Simponi (Golimumab) Efficacy in Treatment of Rheumatoid Arthritis
- Keryx Biopharmaceuticals to Hold Conference Call Tomorrow at 8:30 AM ET to Discuss Top-Line Results from Zerenex Phase 3 Short-Term Study
- Array BioPharma to Present ARRY-520 / KSP Inhibitor Data at 2010 ASH Annual Meeting
- Women With Migraine With Aura Have Better Outcomes After Stroke
